Phenotype Varies for Presumed Pathogenic Variants in KCNB1

Share this content:
Phenotype Varies for Presumed Pathogenic Variants in <i>KCNB1</i>
Phenotype Varies for Presumed Pathogenic Variants in KCNB1

WEDNESDAY, Aug. 16, 2017 (HealthDay News) -- De novo KCNB1 missense and loss-of-function variants are associated with neurodevelopmental disorders, with or without seizures, according to a study published online Aug. 14 in JAMA Neurology.

Carolien G.F. de Kovel, Ph.D., from the University Medical Center in Utrecht, Netherlands, and colleagues examined the clinical spectrum associated with KCNB1 variants. Variants were identified with massive parallel sequencing and confirmed with Sanger sequencing. In all families except one, absence of the variant in the parents could be confirmed with Sanger sequencing.

The researchers found that 20 of the 26 patients with developmental delay carried a missense variant in the ion channel domain of KCNB1, with a concentration of variants in region S5 to S6. Three variants that led to premature stops were located in each of the C-terminal and the ion channel domain. Overall, 21 of 25 patients had seizures, and nine started with epileptic spasms between age 3 and 18 months. All of the patients had developmental delay, with 65 percent experiencing severe developmental delay. Fourteen of the 17 with severe developmental delay had behavioral problems. In four of six patients with stop variants and in a patient with a variant in the S2 transmembrane element rather than the S4 to S6 region, developmental delay was milder.

"The type and position of the variants in the protein are (imperfectly) correlated with the severity of the disorder," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »